Company news

Kura Oncology, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Kura Oncology Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Lymphoma

December 12, 2021

Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia

November 23, 2021

Kura Oncology Reports Third Quarter 2021 Financial Results

November 3, 2021

Kura Oncology to Participate in Credit Suisse Healthcare Conference

November 1, 2021

Kura Oncology to Report Third Quarter 2021 Financial Results

October 27, 2021

Kura Oncology Appoints Teresa Bair as Chief Legal Officer

October 17, 2021

Kura Oncology Reports Second Quarter 2021 Financial Results

August 4, 2021

Kura Oncology to Report Second Quarter 2021 Financial Results

July 28, 2021

Kura Oncology Appoints Helen Collins, M.D. to Board of Directors

July 28, 2021

Kura Oncology Announces Clinical Collaboration to Evaluate Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma

July 5, 2021

Kura Oncology Doses First Patient in Phase 1b Expansion Cohorts with Menin Inhibitor KO-539

June 23, 2021

Kura Oncology to Participate in JMP Securities Life Sciences Conference

June 9, 2021

Kura Oncology Appoints Carol Schafer to Board of Directors

June 3, 2021

Kura Oncology to Participate in Cowen Virtual Oncology Innovation Summit

May 12, 2021

Kura Oncology Reports First Quarter 2021 Financial Results

May 5, 2021

Kura Oncology to Report First Quarter 2021 Financial Results

April 28, 2021

Kura Oncology Announces Publication of Tipifarnib Phase 2 Data in Journal of Clinical Oncology

March 21, 2021

Kura Oncology Reports Fourth Quarter and Full Year 2020 Financial Results

February 23, 2021

Kura Oncology Receives FDA Breakthrough Therapy Designation for Tipifarnib in Head and Neck Squamous Cell Carcinoma

February 23, 2021

Kura Oncology to Participate in Four Upcoming Investor Conferences

February 17, 2021

Kura Oncology to Report Fourth Quarter and Full Year 2020 Financial Results

February 16, 2021

Kura Oncology to Participate in H.C. Wainwright BioConnect 2021 Conference

January 6, 2021

Kura Oncology to Present at J.P. Morgan Healthcare Conference

January 5, 2021

Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

December 10, 2020

Kura Oncology to Participate in the JMP Securities Hematology Summit

December 9, 2020

Kura Oncology Announces Pricing of $300 Million Public Offering of Common Stock

December 7, 2020

Kura Oncology Announces Commencement of Public Offering of Common Stock

December 6, 2020

Kura Oncology Presents First Clinical Data for Menin Inhibitor KO-539 at American Society of Hematology Annual Meeting

December 4, 2020

Kura Oncology to Host Virtual Investor Event on December 5, 2020

November 23, 2020

Kura Oncology Reports Third Quarter 2020 Financial Results

November 4, 2020

Kura Oncology to Report Third Quarter 2020 Financial Results

October 28, 2020

Kura Oncology Reports Preclinical Results Showing Antitumor Activity of Tipifarnib in Combination with PI3Kα Inhibitor in Head and Neck Squamous Cell Carcinoma

October 25, 2020

Kura Oncology Announces Preliminary Data for Menin Inhibitor KO-539 Accepted for Oral Presentation at ASH

October 6, 2020

Kura Oncology Appoints Dr. Stephen Dale as Chief Medical Officer

August 24, 2020

Kura Oncology Reports Second Quarter 2020 Financial Results

August 5, 2020

Kura Oncology to Present at Wedbush PacGrow Healthcare Virtual Conference

August 3, 2020

Kura Oncology to Report Second Quarter 2020 Financial Results

July 29, 2020

Kura Oncology to Participate in JMP Securities Hematology & Oncology Forum

June 10, 2020

Kura Oncology Reports Overall Survival Data from Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinoma

May 28, 2020

Kura Oncology Announces Three Abstracts Accepted for Presentation at ASCO20 Virtual Scientific Program

May 12, 2020

Kura Oncology to Present at BofA Securities Virtual Health Care Conference 2020

May 6, 2020

Kura Oncology Announces Pricing of $125 Million Public Offering of Common Stock

May 5, 2020

Kura Oncology Reports First Quarter 2020 Financial Results

May 3, 2020

Kura Oncology to Report First Quarter 2020 Financial Results

April 28, 2020

Kura Oncology Receives Fast Track Designation for Tipifarnib in T-Cell Lymphomas

March 2, 2020

Kura Oncology Reports Fourth Quarter and Full Year 2019 Financial Results

February 24, 2020

Kura Oncology Announces Transition of Chief Medical Officer

January 22, 2020

Kura Oncology Appoints Kirsten Flowers as Chief Commercial Officer

January 5, 2020

Kura Oncology Receives Fast Track Designation for Tipifarnib in HRAS Mutant HNSCC and Provides Enrollment Guidance for AIM-HN Trial

December 15, 2019

Kura Oncology Reports Clinical and Regulatory Updates for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma

December 7, 2019

← Newer news releases · Older news releases →

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 54 decks. Every deck is listed under its year.